IP Library Granted Patent US 12,385,064
Granted Patent B2
US 12,385,064 · App. 17/705,237 · Granted Aug 12, 2025

Intravitreal dosing for delivery of polynucleotides to retinal cones

Inventors: Claire Gelfman (Carlsbad, CA); Diana Cepeda (San Diego, CA); Ruslan Grishanin (San Francisco, CA); Kristina Bender (Redwood City, CA); Pallavi Sharma (Sunnyvale, CA); Julio Nieves (San Francisco, CA)
C12N15/86C12N2750/14143
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,385,064
App. No.
17/705,237
Granted
Aug 12, 2025
Kind
B2
Abstract

Provided is the intravitreal dosing of recombinant adeno-associated virus (rAAV)-based gene therapies for the treatment of color vision deficiencies such as Blue Cone Monochromacy (BCM) and Red-Green Color Blindness.

Claims (8)

1. An intravitreal dosage form, comprising a recombinant adeno-associated virus (rAAV) vector at a dosage ranging from about 1×10 10 to about 1×10 12 vector genomes (vg)/eye, wherein the rAAV vector comprises a polynucleotide comprising a human L-opsin protein coding sequence operably linked to an M-opsin promoter sequence and followed by a 3′ UTR, and wherein the rAAV vector comprises an AAV2 capsid variant that transduces foveal cone photoreceptors, wherein the polynucleotide comprises a sequence that is at least 95, 98, 99, or 100% identical to the sequence set forth in SEQ ID NO: 3, and which encodes and expresses a biologically-active human L-opsin protein.

2. The intravitreal dosage form of claim 1 , wherein the polynucleotide comprises, in a 5′ to 3′ orientation, a 5′ AAV2 inverted terminal repeat (ITR), a human locus control region (LCR) enhancer sequence, a truncated M-opsin promoter sequence, a 5′ untranslated region (UTR) composed of an M-opsin 5′ UTR with an inserted chimeric intron and a strong Kozak sequence, the human L-opsin protein coding sequence, an M-opsin 3′ UTR, an SV40 polyadenylation sequence, and a 3′ AAV2 ITR.

3. The intravitreal dosage form of claim 1 , wherein the AAV2 capsid variant is an AAV2.7m8 capsid or AAV2.5T.LSV1 capsid that comprises, an amino acid sequence that is at least 95, 98, 99, or 100% identical to the sequence set forth in SEQ ID NO: 1 or 2, and which transduces foveal cone photoreceptors.

4. The intravitreal dosage form of claim 1 , comprising the rAAV vector at a dosage of about 5×10 10 , about 1×10 11 , or about 2×10 11 vg/eye, or optionally about 1×10 10 , about 2×10 10 , about 3×10 10 , about 4×10 10 , about 5×10 10 , about 6×10 10 , about 7×10 10 , about 8×10 10 , about 9×10 10 , about 1×10 11 , about 2×10 11 , about 3×10 11 , about 4×10 11 , about 5×10 11 , about 6×10 11 , about 7×10 11 , about 8×10 11 , about 9×10 11 , or about 1×10 12 vg/eye.

5. The intravitreal dosage form of claim 1 , comprising the rAAV vector at a dosage ranging from about 1×10 10 to about 2×10 10 vg/eye, about 1×10 10 to about 3×10 10 vg/eye, about 1×10 10 to about 4×10 10 vg/eye, about 1×10 10 to about 5×10 10 vg/eye, about 1×10 10 to about 6×10 10 vg/eye, about 1×10 10 to about 7×10 10 vg/eye, about 1×10 10 to about 8×10 10 vg/eye, about 1×10 10 to about 9×10 10 vg/eye, about 1×10 10 to about 1×10 11 vg/eye, about 1×10 10 to about 2×10 11 vg/eye, about 1×10 10 to about 3×10 11 vg/eye, about 1×10 10 to about 4×10 11 vg/eye, about 1×10 10 to about 5×10 11 vg/eye, about 1×10 10 to about 6×10 11 vg/eye, about 1×10 10 to about 7×10 11 vg/eye, about 1×10 10 to about 8×10 11 vg/eye, about 1×10 10 to about 9×10 11 vg/eye, about 1×10 10 to about 1×10 12 vg/eye, about 2×10 10 to about 3×10 10 vg/eye, about 2×10 10 to about 4×10 10 vg/eye, about 2×10 10 to about 5×10 10 vg/eye, about 2×10 10 to about 6×10 10 vg/eye, about 2×10 10 to about 7×10 10 vg/eye, about 2×10 10 to about 8×10 10 vg/eye, about 2×10 10 to about 9×10 10 vg/eye, about 2×10 10 to about 1×10 11 vg/eye, about 2×10 10 to about 2×10 11 vg/eye, about 2×10 10 to about 3×10 11 vg/eye, about 2×10 10 to about 4×10 11 vg/eye, about 2×10 10 to about 5×10 11 vg/eye, about 2×10 10 to about 6×10 11 vg/eye, about 2×10 10 to about 7×10 11 vg/eye, about 2×10 10 to about 8×10 11 vg/eye, about 2×10 10 to about 9×10 11 vg/eye, about 2×10 10 to about 1×10 12 vg/eye, about 3×10 10 to about 4×10 10 vg/eye, about 3×10 10 to about 5×10 10 vg/eye, about 3×10 10 to about 6×10 10 vg/eye, about 3×10 10 to about 7×10 10 vg/eye, about 3×10 10 to about 8×10 10 vg/eye, about 3×10 10 to about 9×10 10 vg/eye, about 3×10 10 to about 1×10 11 vg/eye, about 3×10 10 to about 2×10 11 vg/eye, about 3×10 10 to about 3×10 11 vg/eye, about 3×10 10 to about 4×10 11 vg/eye, about 3×10 10 to about 5×10 11 vg/eye, about 3×10 10 to about 6×10 11 vg/eye, about 3×10 10 to about 7×10 11 vg/eye, about 3×10 10 to about 8×10 11 vg/eye, about 3×10 10 to about 9×10 11 vg/eye, about 3×10 10 to about 1×10 12 vg/eye, about 4×10 10 to about 5×10 10 vg/eye, about 4×10 10 to about 6×10 10 vg/eye, about 4×10 10 to about 7×10 10 vg/eye, about 4×10 10 to about 8×10 10 vg/eye, about 4×10 10 to about 9×10 10 vg/eye, about 4×10 10 to about 1×10 11 vg/eye, about 4×10 10 to about 2×10 11 vg/eye, about 4×10 10 to about 3×10 11 vg/eye, about 4×10 10 to about 4×10 11 vg/eye, about 4×10 10 to about 5×10 11 vg/eye, about 4×10 10 to about 6×10 11 vg/eye, about 4×10 10 to about 7×10 11 vg/eye, about 4×10 10 to about 8×10 11 vg/eye, about 4×10 10 to about 9×10 11 vg/eye, about 4×10 10 to about 1×10 12 vg/eye, about 5×10 10 to about 6×10 10 vg/eye, about 5×10 10 to about 7×10 10 vg/eye, about 5×10 10 to about 8×10 10 vg/eye, about 5×10 10 to about 9×10 10 vg/eye, about 5×10 10 to about 1×10 11 vg/eye, about 5×10 10 to about 2×10 11 vg/eye, about 5×10 10 to about 3×10 11 vg/eye, about 5×10 10 to about 4×10 11 vg/eye, about 5×10 10 to about 5×10 11 vg/eye, about 5×10 10 to about 6×10 11 vg/eye, about 5×10 10 to about 7×10 11 vg/eye, about 5×10 10 to about 8×10 11 vg/eye, about 5×10 10 to about 9×10 11 vg/eye, about 5×10 10 to about 1×10 12 vg/eye, about 6×10 10 to about 7×10 10 vg/eye, about 6×10 10 to about 8×10 10 vg/eye, about 6×10 10 to about 9×10 10 vg/eye, about 6×10 10 to about 1×10 11 vg/eye, about 6×10 10 to about 2×10 11 vg/eye, about 6×10 10 to about 3×10 11 vg/eye, about 6×10 10 to about 4×10 11 vg/eye, about 6×10 10 to about 5×10 11 vg/eye, about 6×10 10 to about 6×10 11 vg/eye, about 6×10 10 to about 7×10 11 vg/eye, about 6×10 10 to about 8×10 11 vg/eye, about 6×10 10 to about 9×10 11 vg/eye, about 6×10 10 to about 1×10 12 vg/eye, about 7×10 10 to about 8×10 10 vg/eye, about 7×10 10 to about 9×10 10 vg/eye, about 7×10 10 to about 1×10 11 vg/eye, about 7×10 10 to about 2×10 11 vg/eye, about 7×10 10 to about 3×10 11 vg/eye, about 7×10 10 to about 4×10 11 vg/eye, about 7×10 10 to about 5×10 11 vg/eye, about 7×10 10 to about 6×10 11 vg/eye, about 7×10 10 to about 7×10 11 vg/eye, about 7×10 10 to about 8×10 11 vg/eye, about 7×10 10 to about 9×10 11 vg/eye, about 7×10 10 to about 1×10 12 vg/eye, about 8×10 10 to about 9×10 10 vg/eye, about 8×10 10 to about 1×10 11 vg/eye, about 8×10 10 to about 2×10 11 vg/eye, about 8×10 10 to about 3×10 11 vg/eye, about 8×10 10 to about 4×10 11 vg/eye, about 8×10 10 to about 5×10 11 vg/eye, about 8×10 10 to about 6×10 11 vg/eye, about 8×10 10 to about 7×10 11 vg/eye, about 8×10 10 to about 8×10 11 vg/eye, about 8×10 10 to about 9×10 11 vg/eye, about 8×10 10 to about 1×10 12 vg/eye, about 9×10 10 to about 1×10 11 vg/eye, about 9×10 10 to about 2×10 11 vg/eye, about 9×10 10 to about 3×10 11 vg/eye, about 9×10 10 to about 4×10 11 vg/eye, about 9×10 10 to about 5×10 11 vg/eye, about 9×10 10 to about 6×10 11 vg/eye, about 9×10 10 to about 7×10 11 vg/eye, about 9×10 10 to about 8×10 11 vg/eye, about 9×10 10 to about 9×10 11 vg/eye, about 9×10 10 to about 1×10 12 vg/eye, about 1×10 11 to about 2×10 11 vg/eye, about 1×10 11 to about 3×10 11 vg/eye, about 1×10 11 to about 4×10 11 vg/eye, about 1×10 11 to about 5×10 11 vg/eye, about 1×10 11 to about 6×10 11 vg/eye, about 1×10 11 to about 7×10 11 vg/eye, about 1×10 11 to about 8×10 11 vg/eye, about 1×10 11 to about 9×10 11 vg/eye, about 1×10 11 to about 1×10 12 vg/eye, about 2×10 11 to about 3×10 11 vg/eye, about 2×10 11 to about 4×10 11 vg/eye, about 2×10 11 to about 5×10 11 vg/eye, about 2×10 11 to about 6×10 11 vg/eye, about 2×10 11 to about 7×10 11 vg/eye, about 2×10 11 to about 8×10 11 vg/eye, about 2×10 11 to about 9×10 11 vg/eye, about 2×10 11 to about 1×10 12 vg/eye, about 3×10 11 to about 4×10 11 vg/eye, about 3×10 11 to about 5×10 11 vg/eye, about 3×10 11 to about 6×10 11 vg/eye, about 3×10 11 to about 7×10 11 vg/eye, about 3×10 11 to about 8×10 11 vg/eye, about 3×10 11 to about 9×10 11 vg/eye, about 3×10 11 to about 1×10 12 vg/eye, about 4×10 11 to about 5×10 11 vg/eye, about 4×10 11 to about 6×10 11 vg/eye, about 4×10 11 to about 7×10 11 vg/eye, about 4×10 11 to about 8×10 11 vg/eye, about 4×10 11 to about 9×10 11 vg/eye, about 4×10 11 to about 1×10 12 vg/eye, about 5×10 11 to about 6×10 11 vg/eye, about 5×10 11 to about 7×10 11 vg/eye, about 5×10 11 to about 8×10 11 vg/eye, about 5×10 11 to about 9×10 11 vg/eye, about 5×10 11 to about 1×10 12 vg/eye, about 6×10 11 to about 7×10 11 vg/eye, about 6×10 11 to about 8×10 11 vg/eye, about 6×10 11 to about 9×10 11 vg/eye, about 6×10 11 to about 1×10 12 vg/eye, about 7×10 11 to about 8×10 11 vg/eye, about 7×10 11 to about 9×10 11 vg/eye, about 7×10 11 to about 1×10 12 vg/eye, about 8×10 11 to about 9×10 11 vg/eye, about 8×10 11 to about 1×10 12 vg/eye, or about 9×10 11 to about 1×10 12 vg/eye.

6. The intravitreal dosage form of claim 5 , comprising the rAAV vector at a dosage ranging from about 6×10 10 to about 6×10 11 vg/eye.

7. The intravitreal dosage form of claim 6 , comprising the rAAV vector at a dosage of about 6×10 10 , about 7×10 10 , about 8×10 10 , about 9×10 10 , about 1×10 11 vg/eye, about 2×10 11 vg/eye, about 3×10 11 vg/eye, about 4×10 11 vg/eye, about 5×10 11 vg/eye, or about 6×10 11 vg/eye.

8. The intravitreal dosage form of claim 6 , comprising the rAAV vector at a dosage ranging from about 6×10 10 to about 7×10 10 vg/eye, about 6×10 10 to about 8×10 10 vg/eye, about 6×10 10 to about 9×10 10 vg/eye, about 6×10 10 to about 1×10 11 vg/eye, about 6×10 10 to about 2×10 11 vg/eye, about 6×10 10 to about 3×10 11 vg/eye, about 6×10 10 to about 4×10 11 vg/eye, about 6×10 10 to about 5×10 11 vg/eye, about 6×10 10 to about 6×10 11 vg/eye, about 7×10 10 to about 8×10 10 vg/eye, about 7×10 10 to about 9×10 10 vg/eye, about 7×10 10 to about 1×10 11 vg/eye, about 7×10 10 to about 2×10 11 vg/eye, about 7×10 10 to about 3×10 11 vg/eye, about 7×10 10 to about 4×10 11 vg/eye, about 7×10 10 to about 5×10 11 vg/eye, about 7×10 10 to about 6×10 11 vg/eye, about 8×10 10 to about 9×10 10 vg/eye, about 8×10 10 to about 1×10 11 vg/eye, about 8×10 10 to about 2×10 11 vg/eye, about 8×10 10 to about 3×10 11 vg/eye, about 8×10 10 to about 4×10 11 vg/eye, about 8×10 10 to about 5×10 11 vg/eye, about 8×10 10 to about 6×10 11 vg/eye, about 9×10 10 to about 1×10 11 vg/eye, about 9×10 10 to about 2×10 11 vg/eye, about 9×10 10 to about 3×10 11 vg/eye, about 9×10 10 to about 4×10 11 vg/eye, about 9×10 10 to about 5×10 11 vg/eye, about 9×10 10 to about 6×10 11 vg/eye, about 1×10 11 to about 2×10 11 vg/eye, about 1×10 11 to about 3×10 11 vg/eye, about 1×10 11 to about 4×10 11 vg/eye, about 1×10 11 to about 5×10 11 vg/eye, about 1×10 11 to about 6×10 11 vg/eye, about 2×10 11 to about 3×10 11 vg/eye, about 2×10 11 to about 4×10 11 vg/eye, about 2×10 11 to about 5×10 11 vg/eye, about 2×10 11 to about 6×10 11 vg/eye, about 3×10 11 to about 4×10 11 vg/eye, about 3×10 11 to about 5×10 11 vg/eye, about 3×10 11 to about 6×10 11 vg/eye, about 4×10 11 to about 5×10 11 vg/eye, about 4×10 11 to about 6×10 11 vg/eye, or about 5×10 11 to about 6×10 11 vg/eye.

Assignments (3)
SECURITY INTEREST Recorded Oct 24, 2025
From: ADVERUM BIOTECHNOLOGIES, INC.; AVALANCHE AUSTRALIA PTY LTD
To: ELI LILLY AND COMPANY
Reel/Frame 072667/0827 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 9, 2025
From: GELFMAN, CLAIRE; CEPEDA, DIANA; GRISHANIN, RUSLAN; BENDER, KRISTINA; SHARMA, PALLAVI; NIEVES, JULIO
To: ADVERUM BIOTECHNOLOGIES, INC.
Reel/Frame 072529/0679 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 16, 2023
From: GELFMAN, CLAIRE; CEPEDA, DIANA; GRISHANIN, RUSLAN; BENDER, KRISTINA; SHARMA, PALLAVI; NIEVES, JULIO
To: ADVERUM BIOTECHNOLOGIES, INC.
Reel/Frame 064609/0755 →
Continuity (3)
Provisional Application 63306004 · Feb 2, 2022
Provisional Application 63166600 · Mar 26, 2021
Related Publication 20230062110A1 · Mar 2, 2023
References Cited (9)
US 11021519B2 · Chalberg, Jr. · 2021 [cited by examiner]
US 11118192B2 · Kirn · 2021 [cited by examiner]
US 11510950B2 · Keravala · 2022 [cited by examiner]
US 20180066022A1 · Chalberg · 2018 [cited by examiner]
US 20190142975A1 · Keravala · 2019 [cited by examiner]
US 20200338146A1 · Keravala · 2020 [cited by examiner]
US 20210069348A1 · Kirn · 2021 [cited by applicant]
Khabou H, Garita-Hernandez M, Chaffiol A, Reichman S, Jaillard C, Brazhnikova E, Bertin S, Forster V, Desrosiers M, Winckler C, Goureau O, Picaud S, Duebel J, Sahel JA, Dalkara D. Noninvasive gene delivery to foveal con… [cited by examiner]
Mancuso K, Hauswirth W W, Li Q, Connor T B, Kuchenbecker J A, Mauck M C, Neitz J, Neitz M, “Gene therapy for red-green colour blindness in adult primates”, Nature, Nature Publishing Group UK, London, London, (Oct. 8, 20… [cited by applicant]